Company intelligence / Profile preview
Genuv
Jung-gu, Seoul, South Koreagenuv.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Genuv’s lead candidate, SNR161/SNR1611NF, is in Phase I/IIa clinical trials for ALS and has shown restoration of CNS function in preclinical models of ALS and Alzheimer’s. The company uses its ATRIVIEW® platform to identify neuroprotective and neurogenerative compounds. Additional programs are at discovery or preclinical stages targeting solid tumors with novel antibodies.[5][8]
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)Fusion proteins
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
– Aiforia Plc. – AI/deep learning technology partnership to enhance ATRIVIEW® drug discovery speed and precision[5]– No major pharma licensing deals disclosed as of now.
Beyond the preview
Go deeper on Genuv.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genuv.